Oculis Holding Ag Is A Clinical Stage Biopharmaceutical Company Based In Zugswitzerlandfocused On Developing Innovative Treatments For Ophthalmic And Neuro Ophthalmic Diseasesthe Company Operates In The U S Icelandeuropeand Chinaaiming To Deliver Life Changing Therapies To Patients Worldwidefounded In 2017 And Publicly Listed On Nasdaq Under The Tickerocssince March 2023Oculis Is Led By Ceo Riad Sherif And Has A Team Of Approximately 49 Employees Oculis Specializes In Topical And Neuroprotective Therapies For Sight Threatening Conditionsits Pipeline Includes Ocs 01A Topical Dexamethasone Formulation In Phase 3 Trials For Diabetic Macular Edema And Post Ocular Surgery Inflammationocs 02A Topical Biologic In Phase 2B Trials For Dry Eye Disease And Uveitisand Ocs 05A Neuroprotective Agent In Development For Various Eye Conditionsthe Company Emphasizes Advanced Topical Delivery Systems To Enhance Drug Effectiveness While Minimizing Systemic Exposureaddressing Unmet Needs In Eye Care
| Company Name | Oculis Sa |
| Country |
Switzerland
|
| Address | N/A |
| Telephone | N/A |
| N/A |
United States